WebJan 18, 2024 · As BLOCKSTONE was conducted in Japan where treating influenza with antivirals is standard of care, all IPs in the study were treated with antivirals including baloxavir. 8 This provided the opportunity to investigate transmission of baloxavir-resistant viruses from baloxavir-treated IPs to HHCs who received placebo prophylaxis. WebSep 1, 2024 · Sunday, Sep 1, 2024 Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk of Developing the Flu After Contact With an Infected Person by 86 Percent BLOCKSTONE study reaches primary endpoint of fewer people testing positive for the flu, with fever and at least one respiratory symptom, when treated with Xofluza …
Genentech: Press Releases Monday, Jun 3, 2024
WebSep 2, 2024 · BLOCKSTONE study reaches primary endpoint of fewer people testing positive for the flu, with fever and at least one respiratory symptom, when treated with Xofluza versus placebo; ... About Xofluza™ (baloxavir marboxil) Xofluza is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has … WebJan 13, 2024 · The European Commission (EC) has granted approval for Roche ’s Xofluza (baloxavir marboxil) to treat and prevent influenza in children aged one year and above. The single-dose oral medicine, Xofluza has been approved to treat uncomplicated influenza and post-exposure prophylaxis of influenza. It has been designed to inhibit the cap … macbook sales pricing
Baloxavir Marboxil: MedlinePlus Drug Information
WebJun 22, 2024 · Baloxavir marboxil is a prodrug that is converted to the active agent baloxavir in the intestines. Baloxavir is metabolized by the liver by UGT1A3 with a minor contribution of CYP 3A4 but demonstrates no significant drug-drug interactions. Baloxavir is administered as a single 40 or 80 mg dose, and the brief exposure and minimal hepatic ... WebProduct Name:XOFLUZA (baloxavir marboxil) tablets, 20 mg and 40 mg Indication:Treatment of acute uncomplicated influenza in patients 12 years of age and … WebMar 27, 2024 · BLOCKSTONE is a Phase III, double-blind, multicenter, randomized, placebo-controlled, post-exposure prophylaxis study that evaluated a single dose of Xofluza compared with placebo in household members (adults and children) in Japan who were living with someone with an influenza infection confirmed by a rapid influenza diagnostic … kitchen residential polished concrete floors